He and hers Earnings will be reported after Monday’s bell report, which gives investors a peek at how its weight loss business continues in the storm of controversy.
The company's stock has been on roller coasters this year Novo Nordisk. On Monday, HIMS investors will be aware of how the company is moving forward after the breakup and how it performs in a few weeks.
Analysts earned $551.7 million, up 74% year-on-year, and earnings per share were $0.15.
Investors are eager for signs of performance in their weight loss business. HIMS does not report revenue from weight loss pills or other processing as order items in its financial reports, although it does set an annual revenue target of $725 million for the weight loss business and tends to spread some numbers in other materials, or tips on its earnings call.
Earnings reports will cover the months of April, May and June. The company had to stop selling exact copies of Novo's Ozempic and Wegovy on May 22, and its partnership with drugmakers exploded on June 23.
HIMS is still selling a “personalized” version of Novo's blockbuster pills, which is why the drugmaker suddenly cut off its cash payment version of its name-branded drug on Telehealth platform. Novo also recently introduced competition for compounds like Hims, although sales of its insured patients also fell.
The Novo-Hims partnership has never been seen as a significant revenue driver. This eases the looming litigation risk from Novo and nods to the company's long-term vision.
On Monday, analysts may ask how HIMS plans to stay in relationships with the moving drugmakers.